Abstract 17138: Intravenous Regadenoson with Aminophylline Reversal is Safe and Equivalent to Intracoronary Adenosine Infusion for Fractional Flow Reserve Measurements
Background: Small studies have shown that Adenosine is equivalent to Regadenoson when obtaining Fractional Flow Reserve (FFR) measurements. A larger study that also evaluates time and safety of aminophylline reversal was yet to be presented.
Methods: After IRB approved consent was obtained, 46 consecutive patients with clinically indicated FFRs were enrolled between 4/2012 and 5/2014. Each patient had FFR measured with adenosine 140 mcg/kg/min IV then allowed to return to baseline. FFR was repeated with Regadenoson 140 mcg IV bolus than reversed with aminophylline 150 mg IV and time to baseline hemodynamics were measured. Tests were compared using linear regression. Reversal time recorded in seconds.
Results: As demonstrated in Figure1 FFR results were similar with both agents, R2 = 0.935, p<0.0001. Also, using the 0.80 cutoff, there was no divergence regarding studies significance. After aminophylline, hemodynamics returned to baseline in 112+/- 72 secs. There were no side-effects reported.
Conclusion: The use of regadenoson for FFR measurements provides results consistent with the ones obtained with adenosine infusion. Aminophilline reversal for regadenoson was fast, well tolerated and safe. Regadenoson with aminophylline reversal may be considered as an alternative for FFR measurements.
Author Disclosures: J. Lee: None. S. Saberian: None. C. White: None. T. Collins: None. J.P. Reilly: None. S. Ramee: None. J.S. Jenkins: None. L. Salvaggio: None. D. Morin: None. R. Patel: None. A. Benjo: None. R. Bober: None.
- © 2014 by American Heart Association, Inc.